戻る
「早戻しボタン」を押すと検索画面に戻ります。 [閉じる]

コーパス検索結果 (１語後でソート)

通し番号をクリックするとPubMedの該当ページを表示します
1 dney but did not have splenectomy or receive recombinant erythropoietin.
2                    All animals also received recombinant erythropoietin.
3 ombosis in patients receiving large doses of recombinant erythropoietin.
4 w probability of benefit from treatment with recombinant erythropoietin.
5 eating anemia in heart failure patients with recombinant erythropoietin and intravenous iron.
6 delivery of dialysis, correcting anemia with recombinant erythropoietin, and controlling the degree o
7 ntithrombin III, infliximab, apotransferrin, recombinant erythropoietin-beta, C1-inhibitor, and gluta
8                                              Recombinant erythropoietin (EPO) analogs [erythropoiesis
9                                              Recombinant erythropoietin (EPO) and iron substitution a
10                    Regular administration of recombinant erythropoietin (EPO) in patients with chroni
11                                              Recombinant erythropoietin (EPO) was introduced into cli
12 antially in their response to treatment with recombinant erythropoietin (EPO).
13        The panellists recommended the use of recombinant erythropoietin in AIHA in the case of inadeq
14                                              Recombinant erythropoietin is expensive and has been lin
15 elivery while awaiting the maximal effect of recombinant erythropoietin on bone marrow red blood cell
16   All patients either had had no response to recombinant erythropoietin or had a high endogenous eryt
17                                              Recombinant erythropoietin promoted resistance to radiot
18                                              Recombinant erythropoietin (rHuEPO, Epogen, Procrit), by
19 t because of increasing safety concerns that recombinant erythropoietin therapy for treating anemia m
20                                Topical human recombinant erythropoietin was applied to encourage angi
21                            Intravenous human recombinant erythropoietin was continued postoperatively
22                                        Human recombinant erythropoietin was first cloned in 1985, and
23 e utility of these yeast strains, functional recombinant erythropoietin was produced.